Recent Updates
Recently added Catalysts

PAZ-417

Phase 1

Alzheimer Disease | Small molecule | Neurology |Pfizer, Inc.|Last Updated: Jan 30, 2009

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment56
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00684710Study Evaluating the Safety, Tolerability and Activity of One Dose of PAZ-417 Given to Healthy Japanese SubjectsPHASE1 COMPLETED 56Apr 1, 2008Aug 1, 2008Jan 30, 20091 Japan
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Safety and Tolerability
3 months
Secondary Endpoints
Pharmacokinetics
3 months
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
PAZ-417EXPERIMENTAL -
PlaceboPLACEBO_COMPARATOR -
Interventions
NameTypeDescription
PAZ-417DRUG -
PlaceboDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range20 Years — N/A
SexMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria 1. Men aged 20 to 45 years inclusive (healthy young male subjects) and ≥65 years inclusive (healthy elderly male subjects) 2. Nonsmoker or smoker of fewer than 10 cigarettes per day. 3. Healthy as determined by the investigator on the basis of medical history, physical examinatio...

Countries:Japan
Unlock Eligibility Criteria